CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update
at the 2019 Bank of America Merrill Lynch Healthcare Conference on
Tuesday, May 14, 2019 at 8:00 a.m. Pacific Time at The Encore Hotel in
A live webcast of Ironwood’s presentation will be accessible through the
Investors section of the company’s website at www.ironwoodpharma.com.
To access the webcast, please log on to the Ironwood website
approximately 15 minutes prior to the start time to ensure adequate time
for any software downloads that may be required. A replay of the webcast
will be available on Ironwood’s website for 14 days following the
About Ironwood Pharmaceuticals
(Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating
medicines that make a difference for patients living with GI diseases.
We discovered, developed and are commercializing linaclotide, the U.S.
branded prescription market leader for adults with irritable bowel
syndrome with constipation (IBS-C) or chronic idiopathic constipation
(CIC). We are currently advancing a Phase IIIb trial evaluating the
efficacy and safety of linaclotide on multiple abdominal symptoms,
including pain, bloating and discomfort, in adult patients with IBS-C.
We are also advancing two late-stage, first-in-category GI product
candidates: IW-3718 is a gastric retentive formulation of a bile acid
sequestrant being developed for the potential treatment of persistent
gastroesophageal reflux disease, and MD-7246 is a delayed-release
formulation of linaclotide that is being evaluated as an oral,
intestinal, non-opioid, pain-relieving agent for patients suffering from
abdominal pain associated with IBS with diarrhea.
Ironwood was founded in 1998 and is headquartered in Cambridge, Mass.
For more information, please visit our newly launched website at www.ironwoodpharma.com
information that may be important to investors will be routinely posted
in both these locations.
Meredith Kaya, 617-374-5082
Vice President, Investor Relations and